A complex preparation for improving muscle wasting syndrome

Abstract

The application discloses a compound preparation beneficial to muscle nutrition, which is composed of yeast extract powder, yeast beta-1, 3-glucan and ginsenoside at a weight ratio of 8:1:1, and contains 200-800 mg of yeast extract powder in each unit of the preparation; wherein the essential amino acids beneficial to muscle nutrition include three branched-chain amino acids, specifically isoleucine, leucine and valine, and the ratio coefficient of the branched-chain amino acids is 1-1.2, and the ratio coefficient range is 0.94-1.14. The compound preparation can improve the symptoms caused by muscle attenuation syndrome, such as muscle weakness, osteoporosis and myocardial function degradation, has the advantages of easy absorption, high safety, synergistic effect and the like, and is suitable for the old, the weak and the people with decreased sports ability.

Description

Technical Field

[0001] This invention belongs to the field of nutrition and functional food technology, specifically relating to a compound nutritional supplement for improving sarcopenia, myasthenia gravis, osteoporosis and myocardial dysfunction, as well as its preparation method and application. Background Technology

[0002] With the increasing aging of society and changes in modern lifestyles, the incidence of sarcopenia and related degenerative diseases (such as osteoporosis, arthritis, and myocardial weakness) has risen significantly. Currently, most nutritional supplements on the market focus on calcium, vitamin D, or cardioprotection, neglecting the nutritional support for muscle tissue itself.

[0003] Branched-chain amino acids (isoleucine, leucine, and valine) are primarily metabolized in muscle and are important substrates for muscle protein synthesis. There are currently no reports on the use of a combination of high-α-aminonitrogen yeast extract, yeast β-1,3-glucan, and ginsenosides to improve sarcopenia. Summary of the Invention

[0004] The purpose of this invention is to address the deficiencies and shortcomings of existing technologies by providing a safe, easily absorbed compound nutritional preparation that can effectively improve sarcopenia and related symptoms.

[0005] To achieve the above objectives, the technical solution adopted by the present invention is as follows: An innovative compound preparation for improving sarcopenia, characterized in that the compound preparation comprises the following active ingredients: Yeast extract powder; Yeast β-1,3-glucan; Ginsenosides; The weight ratio of yeast extract powder, yeast β-1,3-glucan and ginsenosides is 8:1:1.

[0006] Furthermore, the yeast extract content in each unit of the preparation is 200–800 mg, and correspondingly, the yeast β-1,3-glucan content is 25–100 mg, and the ginsenoside content is 25–100 mg.

[0007] Furthermore, the yeast extract has an α-amino nitrogen content of ≥5%, a total nitrogen content of ≥10%, an essential amino acid content of ≥45% of the total amino acids, and an essential amino acid / non-essential amino acid ratio of ≥80%. Among the essential amino acids, those supporting muscle nutrition include three branched-chain amino acids, specifically isoleucine, leucine, and valine, with a ratio coefficient of 1 to 1.2, and the ratio coefficient ranges from 0.94 to 1.14.

[0008] Furthermore, the yeast extract is derived from Candida utilis or Saccharomyces cerevisiae.

[0009] Furthermore, the purity of the yeast β-1,3-glucan is ≥70%, and the molecular weight ranges from 10 to 200 kDa.

[0010] Furthermore, the ginsenosides are derived from American ginseng or ginseng extract, wherein the total content of ginsenosides Rg1, Re, and Rb1 is ≥10%.

[0011] Furthermore, the compound preparation is an oral solid dosage form, including tablets, capsules, granules or powders, and contains pharmaceutically acceptable excipients.

[0012] Furthermore, the excipients include maltodextrin, microcrystalline cellulose, edible starch, and isomaltooligosaccharide.

[0013] It also includes the application of compound preparations in the preparation of functional foods or health products for improving sarcopenia, myasthenia gravis, osteoporosis, myocardial degeneration, or fatigue.

[0014] Compared with the prior art, the beneficial effects of the present invention are as follows: It provides easily absorbed, high-quality branched-chain amino acids, promotes muscle protein synthesis, improves the number and volume of skeletal muscle fibers, and enhances muscle strength.

[0015] Yeast β-1,3-glucan significantly enhances immune function, improves the anti-infection ability of the elderly and frail, and lowers blood lipids.

[0016] Ginsenosides enhance physical strength and anti-fatigue ability, strengthen myocardial contractility, and improve cardiovascular function.

[0017] The three components work synergistically in an 8:1:1 ratio, which is better than the effect of a single component or any combination of two components.

[0018] The product is safe, and all raw materials used are edible, making it suitable for long-term use. Detailed Implementation

[0019] The present invention will now be further described.

[0020] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to specific embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the invention.

[0021] Example 1: A Study on Yeast Extract as a Basis for High-Quality Protein The yeast extract used in this invention is preferably prepared according to a specific process, with an α-amino nitrogen content ≥5.0% and a total nitrogen content ≥10.0%. Amino acid analysis shows that *Candida utilis* contains 45.3% essential amino acids, with an essential amino acid / non-essential amino acid ratio of 83%. The branched-chain amino acid ratio coefficients (RC) are: isoleucine 1.10, leucine 0.94, and valine 1.14, which is close to the standard for egg protein (0.890), indicating that it is a high-quality protein source.

[0022] Example 2: Preferred Formulation of the Invention Candida utilis extract 400mg Yeast β-1,3-glucan 50mg American ginseng extract (ginsenoside content ≥15%) 50mg Microcrystalline cellulose 100-300mg Mix the above raw and auxiliary materials evenly and process them into compressed candies using conventional methods. Each tablet contains 500mg of active ingredients (400mg yeast extract, 50mg β-glucan, and 50mg ginsenosides), with appropriate amounts of excipients. Take 2 tablets twice daily, combined with moderate exercise.

[0023] Example 3: Results Statistics Ten volunteers (aged 55-75) took four tablets of the formulation from Example 2 daily, combined with moderate exercise, and the results after 30 consecutive days are as follows: , No adverse reactions were observed.

[0024] Example 4: Formulations with different amounts of excipients While maintaining the active ingredient ratio of 8:1:1 and the yeast extract dosage of 400 mg, the excipient dosages were adjusted to 100 mg, 200 mg, and 300 mg (excipients were conventional excipients such as edible starch or dextrin) to produce compressed candies. Thirty volunteers were randomly assigned to three groups to take the above three formulations, and there was no significant difference in efficacy (P > 0.05), indicating that the excipient dosage within the range of 100–300 mg does not affect efficacy.

[0025] The above description is only used to illustrate the technical solution of the present invention and is not intended to limit it. Any other modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention, as long as they do not depart from the spirit and scope of the technical solution of the present invention, should be covered within the scope of the claims of the present invention.

Claims

1. A compound preparation for improving sarcopenia, characterized in that, The compound preparation contains the following active ingredients: Yeast extract powder; Yeast β-1,3-glucan; Ginsenosides; The weight ratio of yeast extract powder, yeast β-1,3-glucan and ginsenosides is 8:1:

1.

2. The compound preparation for improving sarcopenia according to claim 1, characterized in that, The yeast extract content in each unit of the preparation is 200-800 mg, and correspondingly, the yeast β-1,3-glucan content is 25-100 mg, and the ginsenoside content is 25-100 mg.

3. The compound preparation for improving sarcopenia according to claim 1 or 2, characterized in that, The yeast extract has an α-amino nitrogen content of ≥5%, a total nitrogen content of ≥10%, an essential amino acid content of ≥45% of the total amino acids, and an essential amino acid / non-essential amino acid ratio of ≥80%. Among the essential amino acids, the branched-chain amino acids that support muscle nutrition include three types: isoleucine, leucine, and valine, with a ratio coefficient of 1 to 1.2, and the ratio coefficient ranges from 0.94 to 1.

14.

4. The compound preparation for improving sarcopenia according to claim 1, characterized in that, The yeast extract is derived from Candida utilis or Saccharomyces cerevisiae.

5. The compound preparation for improving sarcopenia according to claim 1, characterized in that, The purity of the yeast β-1,3-glucan is ≥70%, and the molecular weight ranges from 10 to 200 kDa.

6. The compound preparation for improving sarcopenia according to claim 1, characterized in that, The ginsenosides are derived from American ginseng or ginseng extract, wherein the total content of ginsenosides Rg1, Re, and Rb1 is ≥10%.

7. The compound preparation for improving sarcopenia according to claim 1, characterized in that, The compound preparation is an oral solid dosage form, including tablets, capsules, granules or powders, and contains pharmaceutically acceptable excipients.

8. The compound preparation for improving sarcopenia according to claim 7, characterized in that, The excipients include maltodextrin, microcrystalline cellulose, edible starch, and isomaltooligosaccharide.

9. The use of the compound preparation according to any one of claims 1 to 8 in the preparation of functional foods or health products for improving sarcopenia, myasthenia gravis, osteoporosis, myocardial dysfunction or fatigue.